Pelabresib

Pelabresib
Names
	IUPAC name 2-[(4S)-6-(4-chlorophenyl)-1-methyl-4H-[1,2]oxazolo[5,4-d][2]benzazepin-4-yl]acetamide
	Other names CPI-0610
Identifiers
CAS Number	anhydrous: 1380087-89-7; monohydrate: 1845726-14-8;
3D model (JSmol)	anhydrous: Interactive image; monohydrate: Interactive image;
ChEBI	anhydrous: CHEBI:189653;
ChEMBL	anhydrous: ChEMBL4303404;
ChemSpider	anhydrous: 32738784;
DrugBank	anhydrous: DB17129;
IUPHAR/BPS	anhydrous: 9120;
KEGG	monohydrate: D12266;
PubChem CID	anhydrous: 57389999; monohydrate: 118591411;
UNII	anhydrous: U4017GUQ06; monohydrate: 306QR91I9R;
CompTox Dashboard (EPA)	anhydrous: DTXSID201022544 ;
	InChI InChI=1S/C20H16ClN3O2/c1-11-18-14-4-2-3-5-15(14)19(12-6-8-13(21)9-7-12)23-16(10-17(22)25)20(18)26-24-11/h2-9,16H,10H2,1H3,(H2,22,25)/t16-/m0/s1 Key: GCWIQUVXWZWCLE-INIZCTEOSA-N; monohydrate: InChI=1S/C20H16ClN3O2.H2O/c1-11-18-14-4-2-3-5-15(14)19(12-6-8-13(21)9-7-12)23-16(10-17(22)25)20(18)26-24-11;/h2-9,16H,10H2,1H3,(H2,22,25);1H2/t16-;/m0./s1 Key: LXMGXMQQJNULPR-NTISSMGPSA-N;
	SMILES anhydrous: CC1=NOC2=C1C3=CC=CC=C3C(=N[C@H]2CC(=O)N)C4=CC=C(C=C4)Cl; monohydrate: CC1=NOC2=C1C3=CC=CC=C3C(=N[C@H]2CC(=O)N)C4=CC=C(C=C4)Cl.O;
Pharmacology
ATC code	L01XX84 (WHO)
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Pelabresib (CPI-0610; PELA) is an investigational oral small-molecule drug designed to inhibit bromodomain and extra-terminal domain (BET)-mediated gene transcription involved in the pathogenesis of myelofibrosis (MF) and other myeloproliferative neoplasms. Developed by Constellation Pharmaceuticals, a Novartis company, pelabresib targets epigenetic pathways to modulate oncogenic and inflammatory gene expression, offering a novel therapeutic approach for MF patients with limited treatment options.

As of May 2025, pelabresib is in Phase III clinical trials for MF and has shown promising results in combination with ruxolitinib, a Janus kinase inhibitor (JAKi), but is not yet approved for clinical use.